• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

β受体阻滞剂在心房颤动中的应用——试图理解令人不安的结果。

Beta-blockers in atrial fibrillation-trying to make sense of unsettling results.

机构信息

Department of Medicine, Lillehei Heart Institute, University of Minnesota, 2231 6th Street SE, Minneapolis, MN 55455, USA.

Department of Medicine, Cardiovascular Research Institute of Vermont, University of Vermont, Burlington, VT, USA.

出版信息

Europace. 2023 Feb 16;25(2):260-262. doi: 10.1093/europace/euad010.

DOI:10.1093/europace/euad010
PMID:36748952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9935022/
Abstract

Atrial fibrillation is closely associated with heart failure and adversely affects outcomes. Beta-blockers are strongly recommended to avoid rapid ventricular conduction and tachycardia-induced cardiomyopathy. In this Viewpoint article, we discuss an emerging body of evidence that questions beta-blockers as a preferred rate-control therapy in patients with atrial fibrillation.

摘要

心房颤动与心力衰竭密切相关，并对预后产生不利影响。β受体阻滞剂强烈推荐用于避免快速心室传导和心动过速性心肌病。在这篇观点文章中，我们讨论了越来越多的证据，这些证据对β受体阻滞剂作为心房颤动患者首选的心率控制治疗提出了质疑。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c58/9935022/b2e2db68f591/euad010f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c58/9935022/b2e2db68f591/euad010f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c58/9935022/b2e2db68f591/euad010f1.jpg

相似文献

1
Beta-blockers in atrial fibrillation-trying to make sense of unsettling results.β受体阻滞剂在心房颤动中的应用——试图理解令人不安的结果。
Europace. 2023 Feb 16;25(2):260-262. doi: 10.1093/europace/euad010.
2
An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps.非二氢吡啶类钙通道阻滞剂和β受体阻滞剂在心房颤动及急性失代偿性心力衰竭中作用的最新综述：证据与差距
Cardiovasc Drugs Ther. 2023 Dec;37(6):1205-1223. doi: 10.1007/s10557-022-07334-y. Epub 2022 Mar 31.
3
β-Blockers on Discharge From Acute Atrial Fibrillation Are Associated With Decreased Mortality and Lower Cerebrovascular Accidents in Patients With Heart Failure and Reduced Ejection Fraction.急性房颤出院时使用β受体阻滞剂与射血分数降低的心力衰竭患者死亡率降低及脑血管意外减少相关。
Angiology. 2018 Apr;69(4):316-322. doi: 10.1177/0003319717722283. Epub 2017 Jul 24.
4
Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.β 受体阻滞剂在心力衰竭合并心房颤动患者中的疗效：一项个体化患者数据分析荟萃分析。
Lancet. 2014 Dec 20;384(9961):2235-43. doi: 10.1016/S0140-6736(14)61373-8. Epub 2014 Sep 2.
5
Should β-blockers be used in patients with heart failure and atrial fibrillation?心力衰竭合并心房颤动的患者应该使用β受体阻滞剂吗？
Clin Ther. 2015 Oct 1;37(10):2215-24. doi: 10.1016/j.clinthera.2015.08.017. Epub 2015 Sep 29.
6
Prognostic Significance of Resting Heart Rate and Use of β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry.静息心率及β受体阻滞剂的使用在射血分数降低的心力衰竭患者房颤和窦性心律中的预后意义：来自瑞典心力衰竭登记处的研究结果
Circ Heart Fail. 2015 Sep;8(5):871-9. doi: 10.1161/CIRCHEARTFAILURE.115.002285. Epub 2015 Aug 4.
7
Therapeutic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: From outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy.钠-葡萄糖协同转运蛋白2抑制剂对射血分数保留的心力衰竭患者的治疗作用：从改善结局到对房颤负荷、房颤进展和心房心肌病的潜在有利影响。
Eur J Heart Fail. 2023 Jul;25(7):978-980. doi: 10.1002/ejhf.2891. Epub 2023 May 25.
8
β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation-a meta-analysis.β 受体阻滞剂治疗慢性心力衰竭合并心房颤动患者的全因死亡率：一项荟萃分析。
BMC Cardiovasc Disord. 2019 Jun 3;19(1):135. doi: 10.1186/s12872-019-1079-2.
9
Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial Fibrillation Prevention.β受体阻滞剂在高血压左心室肥厚和预防心房颤动中的应用。
Curr Vasc Pharmacol. 2024;22(1):19-27. doi: 10.2174/0115701611264647231110101700.
10
Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study.老年慢性心力衰竭患者的心房颤动是否会限制卡维地洛的疗效？一项观察性研究的建议。
Ital Heart J. 2005 Apr;6(4):323-7.

引用本文的文献

1
Aging diastole - root cause for atrial fibrillation and heart failure with preserved ejection fraction.舒张期老化——心房颤动和射血分数保留的心力衰竭的根本原因。
J Cardiovasc Aging. 2024 Dec;4(4). doi: 10.20517/jca.2024.22. Epub 2024 Dec 23.
2
Clinical Outcomes of Catheter Ablation for Atrial Fibrillation in Patients with Acute Decompensated Heart Failure.急性失代偿性心力衰竭患者房颤导管消融的临床结局
J Clin Med. 2025 Jan 19;14(2):629. doi: 10.3390/jcm14020629.
3
Impact of Atrial Fibrillation with Rapid Ventricular Response on Atrial Fibrillation Recurrence: From the CODE-AF Registry.

本文引用的文献

1
Rate control drugs differ in the prevention of progression of atrial fibrillation.在预防心房颤动进展方面，控制心率的药物有所不同。
Europace. 2022 Mar 2;24(3):384-389. doi: 10.1093/europace/euab191.
2
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.地高辛与比索洛尔控制心房颤动患者心率对生活质量影响的比较：RATE-AF 随机临床试验。
JAMA. 2020 Dec 22;324(24):2497-2508. doi: 10.1001/jama.2020.23138.
3
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
伴有快速心室反应的心房颤动对心房颤动复发的影响：来自CODE-AF注册研究
J Clin Med. 2024 Sep 14;13(18):5469. doi: 10.3390/jcm13185469.
4
β-blockades and the risk of atrial fibrillation in patients with cardiovascular diseases.β受体阻滞剂与心血管疾病患者心房颤动的风险
Front Pharmacol. 2024 Jun 25;15:1418465. doi: 10.3389/fphar.2024.1418465. eCollection 2024.
5
Complexities of treating co-morbidities in heart failure with preserved ejection fraction.治疗射血分数保留的心力衰竭合并症的复杂性。
ESC Heart Fail. 2024 Oct;11(5):3425-3429. doi: 10.1002/ehf2.14897. Epub 2024 Jun 17.
6
Beta Blockers in Contemporary Cardiology: Is It Better to Cast Them Out?当代心脏病学中的β受体阻滞剂：摒弃它们会更好吗？
Korean Circ J. 2024 Apr;54(4):165-171. doi: 10.4070/kcj.2023.0209.
7
Personalized accelerated physiologic pacing.个性化加速生理性起搏
Eur Heart J Suppl. 2023 Nov 9;25(Suppl G):G33-G43. doi: 10.1093/eurheartjsupp/suad117. eCollection 2023 Nov.
8
Beyond the Rhythm: In Silico Identification of Key Genes and Therapeutic Targets in Atrial Fibrillation.超越节律：心房颤动关键基因和治疗靶点的计算机模拟鉴定
Biomedicines. 2023 Sep 25;11(10):2632. doi: 10.3390/biomedicines11102632.
9
Run baby run … but not too fast! Rate control management in atrial fibrillation: a claim for personalization.快跑，宝贝，快跑……但别太快！心房颤动的心率控制管理：个性化的主张。
Europace. 2023 May 19;25(5). doi: 10.1093/europace/euad117.
2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
4
Catheter Ablation for Atrial Fibrillation with Heart Failure.心力衰竭合并心房颤动的导管消融治疗。
N Engl J Med. 2018 Feb 1;378(5):417-427. doi: 10.1056/NEJMoa1707855.
5
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.β受体阻滞剂治疗射血分数降低、中间范围和保留的心衰：双盲随机试验的个体患者水平分析。
Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564.
6
Ivabradine in stable coronary artery disease without clinical heart failure.稳定性冠状动脉疾病且无临床心力衰竭的伊伐布雷定。
N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.
7
Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials.β受体阻滞剂用于心肌梗死的临床结局：随机试验的荟萃分析
Am J Med. 2014 Oct;127(10):939-53. doi: 10.1016/j.amjmed.2014.05.032. Epub 2014 Jun 11.
8
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南：执行摘要：美国心脏病学会/美国心脏协会实践指南工作组和心律学会的报告
Circulation. 2014 Dec 2;130(23):2071-104. doi: 10.1161/CIR.0000000000000040. Epub 2014 Mar 28.
9
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation.钙通道阻滞剂在永久性心房颤动患者中比β受体阻滞剂改善运动能力并降低 N 末端 B 型利钠肽前体水平。
Eur Heart J. 2014 Feb;35(8):517-24. doi: 10.1093/eurheartj/eht429. Epub 2013 Oct 17.
10
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.依伐布雷定对选择性心率降低对左心室重构和功能的影响：SHIFT 超声心动图子研究结果。
Eur Heart J. 2011 Oct;32(20):2507-15. doi: 10.1093/eurheartj/ehr311. Epub 2011 Aug 29.